Neuro-Bio was featured on Oxfordshire’s local TV channel

08:13


Interview with Neuro-Bio CEO Baroness Professor Susan Greenfield (Video Transcript)

Welcome to the Baroness Susan Greenfield blog. Susan Greenfield is an Oxford-based author, research-scientist, and broadcaster. Elected to the Royal College of Physicians with an Honorary Fellowship in 2000, she has also held research fellowships in College de France, NYU Medical Center, and the Department of Physiology in Oxford. Known for her work in psychology focusing on the brain and consciousness, and in helping people suffering from Alzheimer’s through new research, she has also been awarded 32 Honorary Degrees both from institutions in Britain and in other countries.

Recently, Neuro-Bio was featured on Oxfordshire’s local TV channel. Read the transcript of the video below.

Neuro-Bio is an Oxford University spin-out that's pioneering an alternative approach to talking neurodegenerative diseases such as Alzheimer's. Based at the Culham Science Centre the biotech firm has won millions in funding from a US Company. There’s more in this report.

An Oxfordshire biotech firm which is tackling neuro-degenerative diseases has won £2.5 in funding.

“We are Neuro-Bio, and we are a young company that was founded in 2013, on work that I did a long time ago at Oxford University- well, when I said long time ago, I’ve been doing it right up until 2013, but it’s been for about 30 or 40 years- looking at a new approach why cells in the brain embark on neurodegeneration that characterises Alzheimer’s disease.”

Baroness Susan Greenfield


The investment has come from US –based company Kairos Ventures.

“It’s been a long, hard road, as always in science, to get funding. So, initially we started off with what’s called Angel funding, which as its name suggests, involves people who are prepared to take a very big risk on you. So we start off in 2013 with a few people who believed in us, putting in relatively modest amount of money. When I say modest, not by normal human being standards, but millionaire standards. But nonetheless incurring a high risk. Then on the basis of that, within two or three years, we were able to publish our first paper showcasing what we believe is a new approach with a new drug and then that led to so called series A funding from Venture Capitalist, who are more severe both in their standards for investment but also in the amount of money they invest.”

The money means that Neuro-Bio can expand and move into larger premises at Calhum Science Centre.

“What’s really been a motivating force for me and for the group over these few years is to realise how wonderful it is to have people, literally, put their money where their mouth is and back you up. Some of them realise that if you came to do exciting disruptive research, then that’s best achieved in environments that are conducive to that. So places that are- spaces where you can interact that are exciting, that are a bit funky, a bit unusual, and certainly engender creativity and novel ways of thinking, we were able to expand and rationalise our spaces and having bespoke labs and so, we’re moving into them now and we’re very excited. ”

The biotech firm had been praised for their alternative approach to tackling diseases such as Alzheimer’s.

“People may have heard of the stuff called amyloid, which most people target because there is a rationale that it is there in Alzheimer brains. The problem is it’s also in normal braisn as well. So, althiough it can play a part, I think nowadays, the consensus is that it’s not really the primary driver. It can’t be the primary target. Really, you want to get at the earliest stages, before the amyloid is there. And to us, while there’s ten to twenty years, while the process of neurodegeneration is underway before you get the memory problems, the so call cognitive impairment. So, what we are trying to do is to exploit that window, to see if we can develop a blood biomarker, that would reflect the damage vety early on in the stages, before you have any memory problems.  So, you cna imagine a scenario, you go to the doctor, and he or she says there is good news and bad news. And it’ll be like you had a choelesterol test, you know and the doctor says ‘I’m afraid you have an elevated marker. According to our prediction, in ten years time I’m afraid you’ll start to get memory loss and confusion. But the good news is that we have a drug now that stops any more cells dying.’ So, take that drug now, even though you have no symptoms, take that drug now- and because it stops any more cell loss, it will stop cell loss so the symptoms will never come on. So, that’s the dream. I do stress, this is a dream but we are getting there.”

Neuro-Bio will host an event in April to showcase the company to potential investors and the scientific community.




Keep up-to-date with the latest news and developments on Neuro-Bio and its work in Alzheimer’s research by reading about Baroness SusanGreenfield online. You can also like  Baroness Susan Greenfield Facebook page here. 

You Might Also Like

0 comments